knowledge -WSS

knowledge

author：hotspot 2025-09-06 01:41:12 - browse：9418

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： What American doctors can learn from their Israeli counterparts

WSS

Medicare threatens to cut off funding for HCA's Mission hospital

Why did Pfizer dish out millions for a Super Bowl ad?

A new House health package & hospitals’ new site

Stem cell treatment guidelines are released by FDA

Key House Republican on health care plans exit from Congress

How to fix cancer clinical trials' diversity problem

Wikipedia

knowledge

hotspot

Drug repurposing or repositioning? The language matters

Biden report: The neurospychology of memory and aging

Bright Health sells Medicare Advantage business to Molina

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

As demand for Covid shots wanes, Moderna seeks its next success

Medical mystery: When a cough is not just a cough

Medicare proposal to cover medical devices draws a mixed reaction

Why Novartis is changing the name of its research labs

Sports medicine is finally prioritizing gender equality

Robert F. Kennedy is pitching centrism on health, even on abortion

leisure time

What drug price negotiations mean for Medicare Part D

AstraZeneca chief proposes a novel edit to the drug pricing bill

What should King Charles tell the public about his cancer?

Doctors' information doesn't help them choose wisely when sick

Key House Republican on health care plans exit from Congress

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

focus

focus

hotspot

hotspot